These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27569120)

  • 1. Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s.
    Thomas CE; Mauer EA; Shukla AP; Rathi S; Aronne LJ
    Obesity (Silver Spring); 2016 Sep; 24(9):1955-61. PubMed ID: 27569120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of prescription antiobesity drugs in the United States.
    Hampp C; Kang EM; Borders-Hemphill V
    Pharmacotherapy; 2013 Dec; 33(12):1299-307. PubMed ID: 24019195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of Antiobesity Treatment and Weight-Inducing Antihyperglycemic Agents Among Patients With Type 2 Diabetes in the United States.
    Levin A; Kaur N; Mainoo NK; Perez A
    Clin Ther; 2022 Mar; 44(3):e35-e44. PubMed ID: 35105470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study.
    Viner RM; Hsia Y; Neubert A; Wong IC
    Br J Clin Pharmacol; 2009 Dec; 68(6):844-51. PubMed ID: 20002078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States.
    Suissa K; Schneeweiss S; Kim DW; Patorno E
    Diabetes Obes Metab; 2021 Jul; 23(7):1542-1551. PubMed ID: 33651454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National trends in antiobesity medication use.
    Stafford RS; Radley DC
    Arch Intern Med; 2003 May; 163(9):1046-50. PubMed ID: 12742801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers and Solutions for Prescribing Obesity Pharmacotherapy.
    Fujioka K; Harris SR
    Endocrinol Metab Clin North Am; 2020 Jun; 49(2):303-314. PubMed ID: 32418592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009-2015.
    Saxon DR; Iwamoto SJ; Mettenbrink CJ; McCormick E; Arterburn D; Daley MF; Oshiro CE; Koebnick C; Horberg M; Young DR; Bessesen DH
    Obesity (Silver Spring); 2019 Dec; 27(12):1975-1981. PubMed ID: 31603630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Obesity: Pharmacotherapy Trends of Office-Based Visits in the United States From 2011 to 2016.
    Claridy MD; Czepiel KS; Bajaj SS; Stanford FC
    Mayo Clin Proc; 2021 Dec; 96(12):2991-3000. PubMed ID: 34728060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of new antiobesity drugs.
    Hainer V
    Expert Opin Pharmacother; 2014 Oct; 15(14):1975-8. PubMed ID: 25100293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoption of sodium-glucose cotransporter-2 inhibitors among prescribers caring for nursing home residents.
    Hayes KN; Berry SD; Munshi MN; Zullo AR
    J Am Geriatr Soc; 2023 Aug; 71(8):2585-2592. PubMed ID: 37078149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How physician obesity specialists use drugs to treat obesity.
    Hendricks EJ; Rothman RB; Greenway FL
    Obesity (Silver Spring); 2009 Sep; 17(9):1730-5. PubMed ID: 19300434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
    Gorelik E; Gorelik B; Masarwa R; Perlman A; Hirsh-Raccah B; Matok I
    Int J Obes (Lond); 2020 May; 44(5):1021-1027. PubMed ID: 32152496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness of Antiobesity Drugs for Adolescents With Severe Obesity.
    Mital S; Nguyen HV
    JAMA Netw Open; 2023 Oct; 6(10):e2336400. PubMed ID: 37824146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing for weight loss in primary care: evidence from a population based study.
    Patterson L; Patterson C; Kee F; Hughes C; Donnelly M; O'Reilly D
    J Epidemiol Community Health; 2013 Jun; 67(6):530-2. PubMed ID: 23364026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up.
    Wilding J; Bailey C; Rigney U; Blak B; Kok M; Emmas C
    Prim Care Diabetes; 2017 Oct; 11(5):437-444. PubMed ID: 28583425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current pharmacotherapies for obesity: A practical perspective.
    Golden A
    J Am Assoc Nurse Pract; 2017 Oct; 29(S1):S43-S52. PubMed ID: 29024552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010.
    Xia Y; Kelton CM; Guo JJ; Bian B; Heaton PC
    Obesity (Silver Spring); 2015 Aug; 23(8):1721-8. PubMed ID: 26193062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New chronic disease medication prescribing by nurse practitioners, physician assistants, and primary care physicians: a cohort study.
    Marcum ZA; Bellon JE; Li J; Gellad WF; Donohue JM
    BMC Health Serv Res; 2016 Jul; 16():312. PubMed ID: 27464570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.